Yuxiang Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuxiang Xu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jinglin Gao
Department of Clinical Pharmacology The Fourth Hospital of Hebei Medical University 050011 Shijiazhuang People's Republic of China
2 shared publications - Xiaonan Gao
Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China
2 shared publications - Zhangying Feng
Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China
2 shared publications Hongxin Qie
Department of Clinical Pharmacology The Fourth Hospital of Hebei Medical University 050011 Shijiazhuang People's Republic of China
1 shared publicationJiameng Dong
1 shared publication- Junwei Hu
Shenzhen International Graduate School, Tsinghua University
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-23
A Dual Mechanism-Based Physiologically Based Pharmacokinetic Model for Predicting Mitoxantrone and Liposomal Mitoxantrone Disposition: Preclinical Validation in Rats and Human Extrapolation with Clinical Evaluation
Purpose: This study aimed to develop a physiologically based pharmacokinetic (PBPK) model to quantitatively predict plasma and tissue concentrations of both liposomal-encapsulated and free mitoxantrone in rats and further extrapolate the model to human clinical scenarios. Methods: A dual-compartment PBPK framework was constructed to separately describe the disposition of liposomal carriers and released free mitoxantrone. Global sensitivity analysis (GSA) based on partial rank correlation coefficient (PRCC) was performed to identify key parameters. The external validation was evaluated using rat plasma pharmacokinetic and human clinical data from previous reported studies. Allometric scaling was applied to extrapolate the model to adult humans, and Monte Carlo simulation was utilized to predict clinical plasma concentrations under fixed clinical doses of 20, 30, and 40 mg in lymphoma patients. Results: PRCC analysis results demonstrated that tissue DNA binding capacity (T_DNA) and tissue-to-plasma liposome partition coefficient (Kp_n) were the most dominant parameters governing free drug and liposomal exposure, respectively (PRCC > 0.9). Overall average absolute fold error (AAFE) for tissue predictions was below 2.0. A slightly higher AAFE of 2.16 was observed for free drug submodel, which still complied with the widely accepted 3-fold error threshold for PBPK validation. Model external validation results also demonstrated acceptable predictive capacity of the model for both total and free mitoxantrone concentrations across preclinical and clinical dose levels (AAFE < 3). For human extrapolation, over 92% of clinically observed plasma concentrations from 37 lymphoma patients fell within the model’s 90% predictive interval. Conclusion: This study established a robust, mechanism-driven PBPK model that distinguished encapsulated and free mitoxantrone disposition. The model achieved reliable prediction performance and effectively interprets pharmacokinetic characteristics of PEGylated liposomal mitoxantrone. The present framework provided a valuable mechanistic reference for the construction and optimization of liposomal mitoxantrone PBPK models and supported future translational pharmacokinetic studies of liposomal formulations.
- 1 October 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-23
Open AccessA Dual Mechanism-Based Physiologically Based Pharmacokinetic Model for Predicting Mitoxantrone and Liposomal Mitoxantrone Disposition: Preclinical Validation in Rats and Human Extrapolation with Clinical Evaluation
Purpose: This study aimed to develop a physiologically based pharmacokinetic (PBPK) model to quantitatively predict plasma and tissue concentrations of both liposomal-encapsulated and free mitoxantrone in rats and further extrapolate the model to human clinical scenarios. Methods: A dual-compartment PBPK framework was constructed to separately describe the disposition of liposomal carriers and released free mitoxantrone. Global sensitivity analysis (GSA) based on partial rank correlation coefficient (PRCC) was performed to identify key parameters. The external validation was evaluated using rat plasma pharmacokinetic and human clinical data from previous reported studies. Allometric scaling was applied to extrapolate the model to adult humans, and Monte Carlo simulation was utilized to predict clinical plasma concentrations under fixed clinical doses of 20, 30, and 40 mg in lymphoma patients. Results: PRCC analysis results demonstrated that tissue DNA binding capacity (T_DNA) and tissue-to-plasma liposome partition coefficient (Kp_n) were the most dominant parameters governing free drug and liposomal exposure, respectively (PRCC > 0.9). Overall average absolute fold error (AAFE) for tissue predictions was below 2.0. A slightly higher AAFE of 2.16 was observed for free drug submodel, which still complied with the widely accepted 3-fold error threshold for PBPK validation. Model external validation results also demonstrated acceptable predictive capacity of the model for both total and free mitoxantrone concentrations across preclinical and clinical dose levels (AAFE < 3). For human extrapolation, over 92% of clinically observed plasma concentrations from 37 lymphoma patients fell within the model’s 90% predictive interval. Conclusion: This study established a robust, mechanism-driven PBPK model that distinguished encapsulated and free mitoxantrone disposition. The model achieved reliable prediction performance and effectively interprets pharmacokinetic characteristics of PEGylated liposomal mitoxantrone. The present framework provided a valuable mechanistic reference for the construction and optimization of liposomal mitoxantrone PBPK models and supported future translational pharmacokinetic studies of liposomal formulations.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 10093-10108
Determination of Total and Free Plasma Concentration of Liposomal Mitoxantrone and Clinical Application in Adult Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Purpose: Currently reported methods for determining plasma concentration of mitoxantrone primarily measure total drug concentration. However, methodologies for quantifying liposomal mitoxantrone, particularly the free drug fraction, are lacking. Since the free drug represents the pharmacologically active moiety responsible for therapeutic effects, this study aimed to establish a detection method for total and free concentration of liposomal mitoxantrone in human plasma, while also exploring the temporal changes in drug concentration throughout the dosing cycle for liposomal mitoxantrone. Patients and Methods: For total mitoxantrone, the mobile phase consisted of 10 mmol/L KH2PO4 and methanol, UV detection was performed at a wavelength of 610 nm and protein precipitation was utilized as a pretreatment method. For free mitoxantrone, a gradient elution program in 6.5 min using the mobile phase that made up by 0.2% formic acid and 10mM ammonium acetate water (A) and acetonitrile (B) after a simple pretreatment by solid phase extraction. Sixty-eight total mitoxantrone samples from 35 patients and 61 free mitoxantrone samples from 31 patients with relapsed or refractory peripheral T-cell lymphoma who received intravenous infusions of liposomal mitoxantrone-based chemotherapy regimen were determined. Results: The linear calibration range of total and free mitoxantrone were 0.1– 5 μg/mL and 5– 500 ng/mL (r2> 0.99), respectively. Both intra- and inter-batch precision were less than 10.15%, and the accuracy ranged from 91.07% to 116.82%. The average total concentration in T-cell lymphoma patients after 12 hours of administration was 10.47 μg/mL, while the average free concentration was 272.22 ng/mL. Conclusion: In this study, we established UPLC and UPLC-MS/MS methods for determining the total and free concentrations of liposomal mitoxantrone which were highly efficient, accurate, specific and suitable for clinical application and investigating the pharmacokinetics. Correlation analysis revealed that gender might be an important factor influencing the concentration of liposomal mitoxantrone in patients with relapsed or refractory peripheral T-cell lymphoma.
- 1 November 2025
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 19, 10093-10108
Open AccessDetermination of Total and Free Plasma Concentration of Liposomal Mitoxantrone and Clinical Application in Adult Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Purpose: Currently reported methods for determining plasma concentration of mitoxantrone primarily measure total drug concentration. However, methodologies for quantifying liposomal mitoxantrone, particularly the free drug fraction, are lacking. Since the free drug represents the pharmacologically active moiety responsible for therapeutic effects, this study aimed to establish a detection method for total and free concentration of liposomal mitoxantrone in human plasma, while also exploring the temporal changes in drug concentration throughout the dosing cycle for liposomal mitoxantrone. Patients and Methods: For total mitoxantrone, the mobile phase consisted of 10 mmol/L KH2PO4 and methanol, UV detection was performed at a wavelength of 610 nm and protein precipitation was utilized as a pretreatment method. For free mitoxantrone, a gradient elution program in 6.5 min using the mobile phase that made up by 0.2% formic acid and 10mM ammonium acetate water (A) and acetonitrile (B) after a simple pretreatment by solid phase extraction. Sixty-eight total mitoxantrone samples from 35 patients and 61 free mitoxantrone samples from 31 patients with relapsed or refractory peripheral T-cell lymphoma who received intravenous infusions of liposomal mitoxantrone-based chemotherapy regimen were determined. Results: The linear calibration range of total and free mitoxantrone were 0.1– 5 μg/mL and 5– 500 ng/mL (r2> 0.99), respectively. Both intra- and inter-batch precision were less than 10.15%, and the accuracy ranged from 91.07% to 116.82%. The average total concentration in T-cell lymphoma patients after 12 hours of administration was 10.47 μg/mL, while the average free concentration was 272.22 ng/mL. Conclusion: In this study, we established UPLC and UPLC-MS/MS methods for determining the total and free concentrations of liposomal mitoxantrone which were highly efficient, accurate, specific and suitable for clinical application and investigating the pharmacokinetics. Correlation analysis revealed that gender might be an important factor influencing the concentration of liposomal mitoxantrone in patients with relapsed or refractory peripheral T-cell lymphoma.